医疗大数据分析有助于监测低年龄组乙肝表面抗原阳性率及评估免疫效果

摘要/Abstract

摘要： 目的通过分析临床医疗大数据了解真实世界HBV感染情况和乙型肝炎(乙肝)疫苗免疫策略效果。方法筛选Suvalue数据库中自2006年1月至2017年7月有年龄、性别、HBsAg、抗-HBs、HBeAg和抗-HBc检查结果的数据(包括63家3级及2级医院)。分析总体、不同年龄段及不同性别人群HBsAg、抗-HBs、HBeAg和抗-HBc阳性率随时间变化趋势。并将HBsAg结果与2006年、2014年全国人群乙肝血清流行病学调查结果相比较。结果共2 311 221人纳入研究,其中男性919 908人,女性1 391 313人。所研究人群的HBsAg、HBeAg及抗-HBc阳性率总体呈逐年下降趋势,分别由2006年的17.4%、7.1%、32.9%降至2017年的5.9%、2.3%、24.2%;而抗-HBs呈逐年上升趋势,由2006年的47.6%增加至2017年的56.4%。有意义的是,2006年及2014年1~4岁和5~14岁的HBsAg阳性率(分别为1.4%、9.1%和0.4%、0.9%)与同时期全国人群乙肝血清流行病学调查结果(0.96%、10.6%和0.3%、0.9%)相近(P<0.05)。结论临床医疗大数据分析有助于了解真实世界小年龄组(<15岁)HBV感染状况,从而间接反映国家乙肝疫苗免疫规划的效果。

关键词: HBV, 医疗大数据, 真实世界

Abstract: Objective To better understand HBV infection status and the immunity effects of hepatitis B in the National Immunization Program in real-world clinical practice.Methods Data were retrieved from the SuValue database (including 63 tertiary and secondary hospitals across China) from January 2006 to July 2017. The positive rates of surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core anti-body (anti-HBc) were analyzed and compared with the results of the national seroepidemiological survey of hepatitis B in 2006 and 2014. Results A total of 2 311 221 participants were included in this study, including 919 908 men and 1 391 313 women. From 2006 to 2007, the overall positive rates of HBsAg, HBeAg and anti-HBc declined from 17.4%, 7.1%, 32.9% to 5.9%, 2.3%, 24.2%, whereas the positive rate of anti-HBs increased from 47.6% to 56.4%. Interestingly, the HBsAg positive rate in the groups of 1-4 years and 5-14 years in 2006 (1.4% and 9.1%) and 2014 (0.4% and 0.9%) were close to that in the national seroepidemiological survey of hepatitis B conducted in 2006 (0.96% and 10.6%) and 2014 ( 0.3% and 0.9%, P<0.05).Conclusion The big data from real-world clinical practice can be used to monitor the HBsAg positive rate and evaluate the immunity effect of hepatitis B vaccine in the National Immunization Program those younger than 15 years old.

Key words: HBV, Big medical data, Real world

单姗, 李敏, 田永谦, 孔媛媛, 尤红, 贾继东. 医疗大数据分析有助于监测低年龄组乙肝表面抗原阳性率及评估免疫效果[J]. 肝脏, 2020, 25(5): 472-475.

SHAN Shan, LI Min, TIAN Yong-qian, KONG Yuan-yuan, YOU Hong, JIA Ji-dong. The real-word big data can be used to evaluate the HBsAg positive rate and immunity effects in children[J]. Chinese Hepatolgy, 2020, 25(5): 472-475.

参考文献

[1] GBD 2013 Morality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385: 117-171.
[2] Schweitzer A, Horn J, Mikolajczyk RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet, 2015, 386: 1546-1555.
[3] Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine, 2012, 30: 2212-2219.
[4] WHO. global hepatitis report 2017. Geneva. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ (Accessed April 4, 2019).
[5] Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China . Emerg Infect Dis, 2017, 23:765-772.
[6] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol, 2018, 3:383-403.
[7] Zhang L, Wang H, Li Q, et al. Big data and medical research in China. BMJ, 2018, 360:j5910.
[8] Liang X, Bi S, Yang W, et al. Reprint of: Epidemiological serosurvey of Hepatitis B in China--declining HBV prevalence due to Hepatitis B vaccination. Vaccine, 2013; 31 Suppl 9: J21-28.
[9] 贾继东, 庄辉. 携手推动中国慢性乙型肝炎治疗的可及性. 肝脏杂志, 2016,21: 239-240.
[10] 中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会.乙型肝炎母婴阻断临床管理流程. 中华肝脏病杂志,2017,25:254-256.
[11] Xia GL, Liu CB, Cao HL, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population: results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992. Int Hepatol Commun, 1996, 5:62-73.
[12] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009, 27:6550-6557.
[13] 崔富强, 庄辉. 中国乙型肝炎的流行及控制进展. 中国病毒病杂, 2018, 4:257-264.
[14] 中华人民共和国国家卫生和计划生育委员会. 中国病毒性肝炎防治规划(2017-2020年) . 中国病毒病杂志, 2018, 8:1-7.
[15] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021.http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=04AFF9FBOF68EC73826EC45C613D19777?sequence=1